• $4.0M
    Market Cap
  • -52.87%
    1-Year Change
  • Biotechnology
    Industry
Annual
Quarterly
12/31/2025
12/31/2024
12/31/2023
12/31/2022
Income Statement
Total Operating Revenue
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Cost of Revenue
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Gross Profit
0
N/A
0
N/A
0
N/A
0
N/A
Sales and Marketing Expense
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Research and Development Expense
-574,935
+212.75%
-183,830
-92.40%
-2.4M
-72.54%
-8.8M
+932.44%
Depreciation and Amortization Expense
112,115
-4.40%
117,274
-16.05%
139,694
+85.60%
75,268
+320.91%
Total Operating Expenses
241,032
-24.90%
320,949
-14.53%
375,505
-35.50%
582,192
+230.60%
Operating Profit
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Interest Income
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Interest Expense
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Interest Income and Expense and Net
0
N/A
0
N/A
0
N/A
0
N/A
Total Nonoperating Income and Expense
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Income before Taxes
-2.7M
-19.83%
-3.3M
+53.53%
-2.2M
-77.25%
-9.5M
+474.07%
Income Taxes
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Extraordinary Items
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Net Income
-2.7M
-19.83%
-3.3M
+53.53%
-2.2M
-77.25%
-9.5M
+474.07%
Net Income from Continuing Operations Applicable to Common
-2.7M
-19.83%
-3.3M
+53.53%
-2.2M
-77.25%
-9.5M
+474.07%
Basic EPS and Net Income
-0.56
-51.30%
-1.15
+5.50%
-1.09
+53.52%
-0.71
N/A
Diluted EPS and Net Income
-0.56
-51.30%
-1.15
+5.50%
-1.09
+53.52%
-0.71
-100.00%
Basic Weighted Average Shares
4.7M
+64.48%
2.9M
+45.25%
2.0M
-85.12%
13.3M
N/A
Diluted Weighted Average Shares
4.7M
+64.48%
2.9M
+45.25%
2.0M
-85.12%
13.3M
N/A
Balance Sheet
Cash and Cash Equivalents
864,514
-65.05%
2.5M
-28.25%
3.4M
-75.59%
14.1M
-25.07%
Short-Term Investments
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Cash and Cash Equivalents and Short-Term Investments
864,514
-65.05%
2.5M
-28.25%
3.4M
-75.59%
14.1M
-25.07%
Total Current Assets
1.3M
-52.89%
2.7M
-34.21%
4.1M
-72.42%
14.8M
-26.88%
Accumulated Depreciation
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Property and Plant and Equipment and Net
N/A
N/A
N/A
N/A
23,927
+8.47%
22,058
N/A
Total Long-Term Assets
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Total Assets
2.7M
-34.46%
4.1M
-25.12%
5.5M
-67.36%
16.8M
-23.97%
Income Taxes Payable
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Total Short-Term Debt
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Total Current Liabilities
N/A
N/A
N/A
N/A
294,938
-85.61%
2.1M
+192.48%
Total Long-Term Debt
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Total Long-Term Liabilities
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Total Liabilities
599,071
-20.97%
757,990
-8.23%
825,938
-88.66%
7.3M
+37.52%
Retained Earnings
-23.8M
+12.55%
-21.2M
+18.56%
-17.9M
-6.89%
-19.2M
+97.88%
Total Stockholders Equity
20.2M
+9.14%
18.5M
+298.39%
4.6M
-50.96%
9.5M
-43.44%
Total Shares Outstanding
7.0M
+99.98%
3.5M
+8.32%
3.2M
+268.55%
872,055
-51.15%
Cash Flow
Cash from Operating Activities
-2.8M
-24.74%
-3.7M
-44.12%
-6.6M
-44.99%
-12.0M
+97.41%
Capital Expenditures
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Cash from Investing Activities
-294,953
+657.77%
-38,924
-16.05%
-46,363
-22.75%
-60,016
N/A
Dividends Paid
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Cash from Financing Activities
1.4M
-48.64%
2.8M
+869.85%
-361,044
-105.61%
6.4M
-73.70%
Financials Ratio
Gross Margin
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Operating Margin
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Return on Assets
-78.38%
+13.10%
-69.30%
+256.77%
-19.42%
-60.28%
-48.91%
N/A
Return on Equity
-13.74%
-52.04%
-28.64%
-6.37%
-30.59%
-57.74%
-72.40%
N/A
Revenue Growth
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Current Ratio
N/A
N/A
N/A
N/A
13.80
+91.75%
7.19
N/A
Cash Ratio
N/A
N/A
N/A
N/A
11.69
+69.67%
6.89
N/A
Debt-to-Equity Ratio
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Debt-to-Assets Ratio
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A

Earnings & Revenue History

Debt-to-Assets

Cash Flow